Impact of different diagnostic criteria on the prevalence and prognostic significance of exertional oscillatory ventilation in patients with chronic heart failure

Author(s):  
Lee Ingle ◽  
Aaron Isted ◽  
Klaus K. Witte ◽  
John G.F. Cleland ◽  
Andrew L. Clark

Introduction Exertional oscillatory ventilation (EOV) occurs in many patients with chronic heart failure. Two different definitions of EOV have been proposed by Corrá and Leite. We aimed to compare the prevalence of EOV and its prognostic significance in patients with chronic heart failure using the two diagnostic approaches. Methods Patients underwent a symptom-limited, treadmill-based exercise test with metabolic gas exchange measurements using the modified Bruce protocol. EOV was defined (i) as cyclic fluctuations in ventilation lasting for more than 60% of exercise duration, with an amplitude of greater than 15% of the average amplitude of cyclic fluctuations at rest (Corrá) and/or (ii) as three or more regular oscillations with regularity defined if the standard deviation of three consecutive cycle lengths was within 20% of the average coupled with a minimal average amplitude of ventilatory oscillation of 5I (Leite). Results Two hundred and forty patients (mean age 59 ± 13 years; 73% males; left ventricular ejection fraction 34 ± 6%; peak VO2 21.0 ± 4.6 ml/kg per min; VE/VCO2 slope 35 ± 9) were included in the study. The prevalence of EOV was 25% using the Corrá method and 31% using the Leite method. Fifty percent of patients diagnosed with EOV by the Corrá criteria and 58% diagnosed by the Leite criteria had died at 12-month follow-up. EOV (Corrá) was a predictor of mortality independent of peak VO2, VE/VCO2 slope, left ventricular ejection fraction, age, and 6-min walk test distance. A hazard ratio (HR) of 6.3 ( P < 0.0001; 95% confidence interval = 1.6–25.2) was evident for the Corrá method, which was higher than for the Leite method (HR = 4.9; P < 0.0001; 95% confidence interval = 2.6–18.2). Conclusion The prevalence of EOV was between 25 and 31% depending on the criteria used to define it. The presence of EOV was a powerful predictor of adverse outcome, and diagnosed with the Corrá criteria was associated with a higher HR than the Leite criteria.

2020 ◽  
Vol 90 (1-2) ◽  
pp. 49-58 ◽  
Author(s):  
Wang Chunbin ◽  
Wang Han ◽  
Cai Lin

Abstract. Vitamin D deficiency commonly occurs in chronic heart failure. Whether additional vitamin D supplementation can be beneficial to adults with chronic heart failure remains unclear. We conducted a meta-analysis to derive a more precise estimation. PubMed, Embase, and Cochrane databases were searched on September 8, 2016. Seven randomized controlled trials that investigated the effects of vitamin D on cardiovascular outcomes in adults with chronic heart failure, and comprised 592 patients, were included in the analysis. Compared to placebo, vitamin D, at doses ranging from 2,000 IU/day to 50,000 IU/week, could not improve left ventricular ejection fraction (Weighted mean difference, WMD = 3.31, 95% confidence interval, CL = −0.93 to 7.55, P < 0.001, I2 = 92.1%); it also exerts no beneficial effects on the 6 minute walk distance (WMD = 18.84, 95% CL = −24.85 to 62.52, P = 0.276, I2 = 22.4%) and natriuretic peptide (Standardized mean difference, SMD = −0.39, 95% confidence interval CL = −0.48 to 0.69, P < 0.001, I2 = 92.4%). However, a dose-response analysis from two studies demonstrated an improved left ventricular ejection fraction with vitamin D at a dose of 4,000 IU/day (WMD = 6.58, 95% confidence interval CL = −4.04 to 9.13, P = 0.134, I2 = 55.4%). The results showed that high dose vitamin D treatment could potentially benefit adults with chronic heart failure, but more randomized controlled trials are required to confirm this result.


Sign in / Sign up

Export Citation Format

Share Document